Philadelphia VFC Program

Beginning July 1, 2015, the Philadelphia Vaccines For Children (VFC) Program will cutover entirely to supplying the recently licensed recommended 9-valent human papillomavirus (9vHPV) GARDASIL®9 vaccine to replace the currently supplied 4-valent human papillomavirus (4vHPV) GARDASIL®4 vaccine. Both vaccines are manufactured by Merck, Sharpe and Dohme Corp.
Read the full message here.

Recommended 9vHPV Vaccine Immunization

The ACIP recommended 9vHPV for routine vaccination at 11-12 year for males and females. Catch-up vaccination is recommended for females 13-26 years and males up to 21 years and up to 26 years for MSM and immunocompromised males. The ACIP recommendation overrides the FDA approval.

Starting July 1, the Philadelphia VFC Program will no longer offer 4vHPV. That product will be replaced with 9vHPV. The 9vHPV vaccine follows the same recommended immunization schedule as 4vHPV.

For more information please read the March 27, 2015 ACIP recommendations published in the CDC’s MMWR.